

Date: 12.11.2024

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 531592

Subject: Outcome of the Meeting of Board of Directors held on Tuesday, November 12, 2024.

Dear Sir/ Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, i.e. Tuesday, November 12, 2024, inter alia, other matters:

1. Considered and approved the Un-Audited Standalone & Consolidated Financial Results of the Company along with Limited Review Report of the Auditor for the quarter and half year ended September 30, 2024.

We further inform you that the Board Meeting commenced at 04:00 p.m. today and concluded at 04:40 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,
Genpharmasec Limited

SOHAN
CHATURVEDI

Digitally signed by
SOHAN CHATURVEDI
Date: 2024.11.12
16:42:42 +05'30'



Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728

Encl:

1. Un-Audited Standalone & Consolidated Financial Results for the quarter & half year ended September 30, 2024.
2. Limited Review Report of the Auditor.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist - Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

Board of Directors of

GENPHARMASEC LIMITED

(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of GENPHARMASEC LIMITED (Formerly Known as 'Generic pharma sec Limited') for the quarter ended and half year ended 30th Septemebr, 2024, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.

The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular(s), and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Abhishek S Tiwari & Associates
Chartered Accountants
Firm Reg.No.141048W**



Abhishek Tiwari
Partner

M.No.155947

Date: 12.11.2024

Place of signature: Mumbai

UDIN- 24155947BKCBM4529

GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)
CIN No: L24231MH1992PLC323914
Statement of unaudited financial results for the quarter and half year ended September 30, 2024
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Half Year ended		Year ended
	30th Sept 2024	30th June 2024	30th Sept 2023	30th Sept 2024	30th Sept 2023	31st March 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	576.95	530.29	785.86	1,107.24	1,382.26	3,040.57
II. Other Income	85.82	57.79	15.23	143.01	26.42	71.76
III. Total Income (I + II)	662.77	588.08	801.09	1,250.85	1,408.68	3,112.33
IV. Expenses:						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchase of Stock-in-Trade	536.23	547.24	560.95	1,083.57	1,176.91	2,339.62
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-59.32	-119.11	102.51	-178.43	-70.70	83.39
(d) Employee benefit expense	14.02	17.29	16.96	31.31	36.75	78.42
(e) Financial costs	4.05	7.11	6.50	11.17	12.79	39.48
(f) Depreciation and amortization expense	4.26	0.49	0.08	4.75	0.78	1.87
(g) Other expenses	80.39	61.76	109.55	122.15	241.15	524.85
V. Total Expenses	559.64	514.88	790.55	1,074.52	1,397.68	3,065.67
VI. Profit before tax (III - V)	103.13	73.20	4.54	176.33	11.00	46.66
Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred Tax	-3.36	-14.33	-3.75	-17.69	-7.59	-42.02
(3) Prior Period Tax	-	-	-	-	-	-0.03
VII. Total Tax Expense	-3.36	-14.33	-3.75	-17.69	-7.59	-42.05
VIII. Profit for the period (VI-VII)	99.77	58.87	0.79	158.64	3.41	4.62
Other Comprehensive Income/(Loss)						
(i) Items that will not be reclassified to Profit and Loss						
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	-
(b) Income tax effect on above	-	-	-	-	-	-
(c) Equity instrument through other comprehensive income	-15.18	22.42	-3.45	7.24	74.88	-73.04
(d) Income tax effect on above	-	-	-	-	-	-
IX. Total Other Comprehensive Income / (Loss)	-15.18	22.42	-3.45	7.24	74.88	-73.04
X. Total Comprehensive Income/(Loss) for the year (VIII + IX) (Comprising profit and other comprehensive income for the year)	84.59	81.29	-2.66	165.88	78.29	-68.42
Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	5,537.20	5,537.20	2,768.60	5,537.20	2,768.60	5,537.20
Other Equity	-	-	-	-	-	919.57
XI. Earning per equity share						
(a) Basic	0.02	0.01	0.00	0.03	0.00	0.00
(b) Diluted	0.02	0.01	0.00	0.03	0.00	0.00

Notes:


- The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 12th November, 2024.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The review report does not contain any qualification. The above financial result along with review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- Segment Reporting has been annexed in Annexure 1.
- The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors.
- The results for the quarter ended 30th September 2024 are the balancing figure between in respect of the half year ended results as on 30th September 2024 and published unaudited financial results for the quarter ended 30th June 2024.
- The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October, 2021
- The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd to expand the business activities on 29th January 2024
- During the quarter ended 31st March, 2024, the company made investment in M/s. Derren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:

The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.

The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.

The acquisition was estimated to be completed by 19th September 2024. However, due to pending execution of SPA & SSA, Genpharmasec Ltd, the company, has not gained 'controlling interest' as on the date of these results.
- The Company has brought forward losses, which are set-off against the profit hence provision for current tax is not provided.
- The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,859 shares to the Equity Shareholders of the Company through Right Issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)


Sahan Chaturvedi

(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728

PLACE : MUMBAI
Date : 12.11.2024



GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)
CIN No: L24231MH1992PLC323914

Balance Sheet as at September 30, 2024

(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
ASSETS		
1. Non-current assets		
(a) Plant Property and Equipments	9.66	10.16
(b) Right to Use Assets	34.35	-
(c) Financial Assets		
(i) Non - Current Investment	2,036.51	1,783.69
(ii) Loans and Advances	2,262.86	1,207.22
(iii) Security Deposits	3.61	-
(iii) Others	954.02	-
(d) Other Non Current Assets	0.91	-
(e) Deferred Tax Assets (Net)	24.47	42.60
	5,326.40	3,043.67
2. Current assets		
(a) Inventories	1,062.65	884.22
(b) Financial Assets		
(i) Investments	-	168.39
(i) Trade Receivable	557.42	909.99
(ii) Cash and Cash Equivalents	49.85	291.67
(ii) Bank Balances Other than above	318.80	1,566.20
(iv) Loans and Advances	14.32	0.69
(c) Current Tax Assets (net)	13.14	4.94
(c) Other Current Assets	117.69	177.70
	2,133.88	4,003.78
Total -Assets	7,460.28	7,047.46
EQUITY AND LIABILITIES		
I. Equity		
(a) Equity Share Capital	5,537.20	5,537.20
(b) Other Equity	1,085.45	919.57
	6,622.64	6,456.77
II. Liabilities		
1. Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	321.10	321.04
(ii) Lease Liabilities	21.51	-
	342.61	321.04
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables		
a) Total outstanding dues of micro enterprises and small enterprises	455.90	11.73
b) Total outstanding dues of creditors other than micro enterprises	13.24	226.05
(iii) Lease liabilities	13.54	-
(iv) Others Financial liabilities	4.69	-
(b) Other Current Liabilities	-	31.86
(c) Provisions	7.66	-
	495.03	269.65
TOTAL - EQUITY AND LIABILITIES	7,460.28	7,047.46

For and on Behalf of the Board of Directors of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi

(WHOLE TIME DIRECTOR & CFO)

DIN : 09629728

PLACE : MUMBAI
Date : 12.11.2024



GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)
CIN No: L24231MH1992PLC323914

Cash flow statement for the period ended 30th September 2024
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at September 30, 2024 (Unaudited)	As at September 30, 2023 (Unaudited)
A) Cash Flow from Operating Activities		
Net Profit Before Tax	176.33	11.01
Add : Adjustment for :		
Depreciation	4.75	0.78
Loss Allowance	20.24	21.92
Interest Income	(143.61)	(18.42)
Provisions	7.66	
Finance Cost	11.17	12.79
Operating Profit before Working Capital Changes	76.54	28.08
Add : Adjustment for		
Inventories	(178.43)	(70.70)
Trade Receivables	332.33	(47.77)
Other Financial Assets	(3.85)	-
Other Current Tax Assets	-	0.76
Other Current Assets	60.23	(57.89)
Trade payables	231.35	41.66
Other Financial Liabilities	4.69	348.10
Other Current Liabilities	(31.86)	4.58
Net Changes in Working Capital	414.46	218.74
Cash Generated from Operations	491.00	246.82
Less : Direct Taxes Paid	(8.20)	(1.89)
Net Cash Generated from Operating Activities	482.80	244.93
B) Cash Flow from Investing Activities		
Purchase of Fixed Assets	(0.50)	(0.28)
Investments made	(89.70)	(8.68)
FD created	(954.02)	-
Loans given	(1,055.64)	(171.54)
Interest Received	156.35	18.42
Net Cash used in Investment Activities	(1,943.52)	(162.08)
C) Cash Flow from Financing Activities		
Proceeds from Long term Borrowings	0.06	8.15
Payment of Lease liability	(4.67)	-
Loan Redeemed	(13.63)	-
Finance charges paid	(10.25)	(12.79)
Net Cash generated/(used) in Financing Activities	(28.49)	(4.64)
Net Increase/ (Decrease) in Cash & Cash Equivalents (A+B+C)	(1,489.21)	78.21
Add : Balance at the beginning of the year	1,857.86	199.32
Cash and Cash Equivalents at the close of the year	368.65	277.53

Notes

The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of cash flow

For and on Behalf of the Board of Directors of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728

PLACE : MUMBAI
Date : 12.11.2024



GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)

ANNEXURE - I

Statement of unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Period Ended 30th September, 2024

(Rs. in Lakhs)

Particulars	Quarter Ended			Half Year Ended	Half Year Ended	Year Ended
	30th September 2024	30th June 2024	30th September 2023	30th September 2024	30th September 2023	31st March 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
Pharmaceuticals	576.95	530.29	785.86	1,107.24	1,382.26	3,040.57
Trading in Securities	-	-	-	-	-	-
Total	576.95	530.29	785.86	1,107.24	1,382.26	3,040.57
Segment Results (Profit before tax and interest)						
Pharmaceuticals	106.19	79.55	43.27	185.74	40.58	225.06
Trading in Securities	-	-	(2.54)	-	55.68	54.28
Total	106.19	79.55	40.73	185.74	96.26	279.34
Less						
(i) Unallocated Finance Cost	(3.06)	(6.35)	-	(9.41)	-	-
(ii) Other unallocable expenditure net of unallocable income	-	-	(36.18)	-	(85.26)	(232.68)
(iii) Inter-Segment Eliminations	-	-	-	-	-	-
Profit Before Tax	103.13	73.20	4.55	176.33	11.01	46.66
Segment Assets						
Pharmaceuticals	2,791.92	3,322.85	1,574.73	2,791.92	1,574.73	1,835.25
Trading in Securities	-	126.03	126.58	-	126.58	126.03
Un-Allocated	4,667.95	3,655.29	341.58	4,667.95	341.58	5,886.18
Total	7,459.88	7,104.17	2,042.89	7,459.88	2,042.89	7,047.46
Segment Liabilities						
Pharmaceuticals	516.13	245.07	182.35	516.53	182.35	259.65
Trading in Securities	-	-	-	-	-	-
Un-Allocated	321.10	321.04	259.24	321.10	259.24	321.04
Total	837.23	566.11	441.59	837.63	441.59	590.70

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728

PLACE : MUMBAI
Date : 12.11.2024





Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist - Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

Board of Directors of

GENPHARMASEC LIMITED

(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

Opinion

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results (the Statement') of GENPHARMASEC LIMITED (Formerly Known as 'Generic pharmasec Limited') (the Holding Company') and its Subsidiary (the Holding Company and its Subsidiary together referred to as "the Group") (Refer annexure -1 for the list of entities included in the Statement) for the Quarter ended and Half year ended as on 30th September, 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. Based on our review conducted as below and based on the consideration of the review reports as referred to in paragraph 5 nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular(s), and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement

Basis for Opinion

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist - Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

5. We did not review the interim financial results of two subsidiaries included in the Statement, which have not been reviewed by their auditors and whose financial information reflects total assets of Rs. 748.40 Lacs as at 30th September, 2024, total revenue of Rs 26.62 Lacs and Rs. 30.26 Lacs, total net loss after tax of Rs 29.40 Lacs and Rs. 55.41 Lacs for the quarter ended and half year ended 30th September, 2024 respectively have been furnished to us by the Holding Company's management. Our conclusion on the Statement, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular, in so far as it relates to the aforesaid subsidiaries, is based solely on such unreviewed interim financial results. According to the information and explanations given to us by the management, this interim financial result is not material to the Group.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors

For Abhishek S Tiwari & Associates
Chartered Accountants
Firm Reg.No.141048W



Abhishek Tiwari
Partner

M.No.155947

Place of signature: Mumbai

Date: 12.11.2024

UDIN- 24155947BKCBNCN5563



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander (East), Dist - Thane, Maharashtra-401105

Mob 9029326651, Email: caabhishek2012@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure -1

List of entities included in the statement

Sr.No.	Name of the entity	Nature of relationship
1	Clingenome India Private Limited	100 % Subsidiary
2	Genpharmasec Middle East DMCC	52 % Subsidiary

GENPHARMASEC LIMITED

(Formerly known as Generic Pharmasec Ltd)

CIN No: L24231MH1992PLC323914

Consolidated Statement of unaudited financial results for the quarter and half year ended September 30, 2024

(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Half Year ended	Half Year ended	Year ended
	30th Sept 2024	30th June 2024	30th Sept 2023	30th Sept 2024	30th Sept 2023	31st March 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	603.31	519.50	785.86	1,322.80	1,382.26	3,040.57
II. Other income	74.74	86.75	15.23	131.34	35.42	85.59
III. Total Income (I + II)	678.04	606.25	801.09	1,454.14	1,417.68	3,126.16
IV. Expenses:						
(a) Cost of materials consumed	11.10	35.91	-	47.31	-	-
(b) Purchase of Stock-in-Trade	536.23	532.89	580.95	1,069.12	1,175.91	2,339.92
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-46.58	-162.08	102.51	-200.98	-70.70	83.53
(d) Employee benefit expense	19.32	17.58	16.96	36.91	35.75	76.42
(e) Financial costs	6.95	10.19	6.50	17.15	12.79	40.91
(f) Depreciation and amortization expense	30.03	15.80	0.08	45.83	0.78	4.21
(g) Other expenses	72.62	65.05	109.65	137.87	241.15	536.33
V. Total Expenses	627.57	629.14	796.55	1,152.70	1,387.88	3,011.19
VI. Profit before tax (III - V)	50.47	51.11	4.54	101.44	11.00	25.06
Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred Tax	19.89	-18.11	-3.75	1.78	-7.59	-4.02
(3) Prior Period Tax	-	-	-	-	-	0.03
VII. Total Tax Expense	19.89	-18.11	-3.75	1.78	-7.59	-4.19
VIII. Profit/(Loss) for the period (VI-VII)	70.37	33.06	9.29	103.22	3.41	-16.93
Other Comprehensive Income/(Loss)						
(i) Items that will not be reclassified to Profit and Loss						
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	-
(b) Income tax effect on above	-	-	-	-	-	-
(c) Equity instrument through other comprehensive income	-15.18	22.42	-3.45	7.24	74.88	-73.04
(d) Income tax effect on above	-	-	-	-	-	-
IX. Total Other Comprehensive Income / (Loss)	-15.18	22.42	-3.45	7.24	74.88	-73.04
X. Total Comprehensive Income/(Loss) for the year (VIII + IX) (Comprising profit and other comprehensive income for the year)	55.19	55.42	-2.66	110.46	78.29	-89.97
Profit/(Loss) Attributable to Non-controlling Interest	-2.52	-0.23	-	-2.74	-	-4.37
Profit/(Loss) Attributable to Parent	57.70	55.64	-2.66	113.21	78.29	-85.60
Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	5,537.20	5,537.20	2,768.60	5,537.20	2,768.60	5,537.29
Other Equity	-	-	-	-	-	802.35
XI. Earning per equity share						
(a) Basic	0.01	0.01	0.00	0.02	0.00	-0.00
(b) Diluted	0.01	0.01	0.00	0.02	0.00	-0.00

Notes:

- The consolidated figures represent the financial data for the holding company, Genpharmasec Limited, along with its two subsidiaries: Clinigenome India Private Limited and Genpharmasec Middle East DMCC.
- The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 12th November, 2024.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The review report does not contain any qualification. The above financial result along with review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- Segment Reporting has been annexed in Annexure 1.
- The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors
- The results for the quarter ended 30th September 2024 are the balancing figure between in respect of the half year ended results as on 30th September 2024 and published unaudited financial results for the quarter ended 30th June 2024.
- The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October, 2021
- During the quarter ended 31st March, 2024; the company made investment in M/s. Darren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:
The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.
The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.
The acquisition was estimated to be completed by 19th September 2024. However, due to pending execution of SPA & SSSA, Genpharmasec Ltd, the company, has not gained 'controlling interest' as on the date of these results.
- The Company has brought forward losses, which are set-off against the profit hence provision for current tax is not provided.
- The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right Issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

For and on behalf of the Board of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan
Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)

DIN : 00629728

PLACE : MUMBAI
Date : 12.11.2024



GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)
CIN No: LZ4231MH1992PLC323914

Consolidated Balance Sheet as at September 30, 2024

(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at 30 September 2024 (Unaudited)	As at 31 March 2024 (Audited)
ASSETS		
1. Non-current assets		
(a) Plant Property and Equipments	467.28	83.90
(b) Right to Use Assets	163.14	-
(c) Financial Assets		
(i) Non - Current Investment	1,939.59	1,763.95
(ii) Loans and Advances	1,703.20	1,124.72
(iii) Security Deposit	11.47	-
(iv) Others	954.02	-
(d) Other Non Current Assets	85.82	-
(e) Deferred Tax Assets (Net)	43.94	42.60
	5,368.46	3,015.17
2. Current assets		
(a) Inventories	1,085.20	884.22
(b) Financial Assets		
(i) Investments	-	168.39
(ii) Trade Receivable	554.76	909.59
(iii) Cash and Cash Equivalents	63.17	316.96
(iv) Bank Balances Other than above	318.80	1,566.20
(v) Loans and Advances	14.32	0.69
(c) Current Tax Assets (net)	13.95	4.94
(c) Other Current Assets	119.71	246.01
	2,169.90	4,097.39
Total -Assets	7,538.36	7,112.56
EQUITY AND LIABILITIES		
I. Equity		
(a) Equity Share Capital	5,537.20	5,537.20
(b) Other Equity	1,002.71	902.34
(c) Non Controlling Interest	11.21	13.95
	6,551.11	6,453.49
II. Liabilities		
1. Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	321.10	321.04
(ii) Lease Liabilities	127.95	67.83
	449.05	388.87
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables		
a) Total outstanding dues of micro enterprises and small enterprises	464.68	11.73
b) Total outstanding dues of creditors other than micro enterprises	18.75	226.16
(iii) Lease liabilities	40.36	-
(iv) Others Financial liabilities	6.74	-
(b) Other Current Liabilities	-	32.31
(c) Provisions	7.66	-
	538.20	270.20
TOTAL - EQUITY AND LIABILITIES	7,538.36	7,112.56

For and on Behalf of the Board of Directors of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728

PLACE : MUMBAI
Date : 12.11.2024



GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)
CIN No: L24231MH1992PLC323914

Consolidated Cash flow statement for the period ended 30th September 2024
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at September 30, 2024 (Unaudited)	As at September 30, 2023 (Unaudited)
A) Cash Flow from Operating Activities		
Net Profit Before Tax	101.44	11.01
Add : Adjustment for :		
Depreciation	45.63	0.78
Provisions	7.66	-
Interest Income	(131.34)	(18.41)
Loss Allowance	20.24	21.92
Finance Cost	17.15	12.79
Operating Profit before Working Capital Changes	60.78	28.09
Add : Adjustment for		
Inventories	(200.98)	(70.70)
Trade Receivables	334.99	(47.77)
Other Current Assets	126.30	(57.89)
Other Current Tax Assets	-	0.76
Other Non Current Assets	(84.03)	-
Other Financial Assets	(11.19)	-
Trade payables	245.55	41.66
Other Financial Liabilities	6.74	348.10
Other Current Liabilities	(32.31)	4.58
Net Changes in Working Capital	385.08	218.74
Cash Generated from Operations	445.87	246.83
Less : Direct Taxes Paid	(9.02)	(1.89)
Net Cash Generated from Operating Activities	436.85	244.94
B) Cash Flow from Investing Activities		
Purchase of Fixed Assets	(410.38)	(0.28)
Investments made	(26.99)	(8.68)
FD Created	(954.02)	-
Loan Given	(592.12)	(171.54)
Interest Received	143.85	18.42
Net Cash used in Investment Activities	(1,839.67)	(162.08)
C) Cash Flow from Financing Activities		
Proceeds from Long Term Borrowings	0.06	8.14
Payment of Lease liability	(88.72)	-
Finance charges paid	(9.71)	(12.79)
Net Cash used in Financing Activities	(98.37)	(4.65)
Net Increase/ (Decrease) in Cash & Cash Equivalents (A+B+C)	(1,501.19)	78.22
Add : Balance at the beginning of the year	1,883.16	199.31
Cash and Cash Equivalents at the close of the year	381.97	277.53

Notes

The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of cash flow

The company has invested in subsidiary in quarter ended on 31st March'24. Hence, for September 23, consolidated cash flow is same as standalone cash flow already presented separately.

For and on Behalf of the Board of Directors of
Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan
Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728



PLACE : MUMBAI
Date : 12.11.2024

GENPHARMASEC LIMITED
(Formerly known as Generic Pharmasec Ltd)
"ANNEXURE - I"

Statement of unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter & Year Ended 30th September 2024

Particulars	Quarter Ended			Half Year Ended	Half Year Ended	Year Ended
	30/09/2024	30/06/2024	30-09-2023	30/09/2024	30/09/2023	31/03/2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue						
Pharmaceuticals	576.85	515.84	785.66	1,092.79	1,382.26	3,040.57
Trading in Securities	-	-	-	-	-	-
Laboratory Testing	26.35	3.66	-	30.01	-	-
Total Revenue	603.31	519.50	785.66	1,122.80	1,382.26	3,040.57
Segment Results (Profit before tax and interest)						
Pharmaceuticals	106.19	79.55	43.27	185.74	40.58	225.06
Trading in Securities	-	-	-2.54	-	55.88	54.28
Laboratory Testing	-33.83	-17.91	-	-51.74	-	-
Unallocable	-4.59	-0.07	-	-4.86	-	-
Total	67.78	61.56	40.73	129.34	96.26	279.34
Less						
(i) Finance Cost	-17.30	-10.60	-	-27.90	-	-
(ii) Other unallocable expenditure net of unallocable income	-	-	-36.18	-	-85.25	-232.69
(iii) Inter-Segment Eliminations	-	-	-	-	-	-
Profit Before Tax	50.48	50.96	4.55	101.44	11.01	46.65
Segment Assets						
Pharmaceuticals	1,874.45	3,389.44	1,574.73	1,874.45	1,574.73	1,881.00
Trading in Securities	-	126.03	126.58	-	126.58	126.03
Laboratory Testing	741.19	615.42	-	741.19	-	-
Un-Allocated	4,922.72	3,275.01	341.58	4,922.72	341.58	5,105.55
Total	7,538.36	7,415.90	2,042.89	7,538.36	2,042.89	7,112.58
Segment Liabilities						
Pharmaceuticals	516.53	245.07	182.35	516.53	182.35	230.22
Trading in Securities	-	-	-	-	-	-
Laboratory Testing	140.41	185.70	-	140.41	-	-
Un-Allocated	330.31	350.19	259.24	330.31	259.24	426.85
Total	987.25	780.96	441.59	987.25	441.59	659.07

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

Genpharmasec Limited
(Formerly known as Generic Pharmasec Ltd)

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR & CFO)
DIN : 09629728

PLACE : MUMBAI
Date : 12.11.2024

